FULC
Fulcrum Therapeutics, Inc.
Set alert
3.71 USD -0.06 -1.59%
3.68 Day range 3.76
3.14 52-week range 14.60
- YTD
- -67.20%
- 1 year
- -56.86%
- Open
- 3.74
- Prev close
- 3.77
- Mkt cap
- 283.38M
- Vol
- 933.22K
- Avg vol
- 1.57M
- EPS
- -1.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.68
- High
- 3.76
- Forward P/E
- -3.84
- Beta
- 2.23
- Short ratio
- 7.67
- Inst. own
- 89.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 31, 2024
- 50-d avg
- 3.58
- 200-d avg
- 6.57
- 1y target
- 5.29
Financial health
Altman Z-Score
10.41 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-3 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -9.6×
FY 2017 5y median -8.0× FY 2025
P/S 0.0×
FY 2017 5y median 32.6× FY 2025
P/B 2.1×
FY 2017 5y median 1.8× FY 2025
P/FCF -11.9×
FY 2017 5y median -7.8× FY 2025
EV/EBITDA -7.2×
FY 2017 5y median -7.2× FY 2025
EV/Sales 0.0×
FY 2017 5y median 30.8× FY 2025
FCF Yield -8.4%
FY 2017 5y median -12.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2017 5y median -263.7% FY 2025
Operating Margin 0.0%
FY 2017 5y median -423.0% FY 2025
Net Margin 0.0%
FY 2017 5y median -421.9% FY 2025
ROE -21.5%
FY 2017 5y median -38.2% FY 2025
ROIC -23.8%
FY 2017 5y median -37.6% FY 2025
ROA -20.4%
FY 2017 5y median -34.4% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2017 FY 2025
Operating Income -287.1%
FY 2017 FY 2025
EPS (diluted) -637.5%
FY 2017 FY 2025
Free Cash Flow -2319.0%
FY 2017 FY 2025
Financial Health
Current Ratio 27.4×
FY 2017 5y median 17.7× FY 2025
Quick Ratio 27.4×
FY 2017 5y median 17.7× FY 2025
Debt / Equity 0.0×
FY 2017 5y median 0.0× FY 2025
Net Debt / EBITDA 2.6×
FY 2017 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31